Cytosorbents targets operating cash flow breakeven in 2H 2026 while planning DrugSorb-ATR de novo submission in late 2026/early 2027
Cytosorbents Corp. · Now $0.47
-18% since the alert
$0.57 → $0.47
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS